GVHD,Acute Clinical Trial
Official title:
Effects of a Physical Therapy and Therapeutic Exercise Program in Graft-versus-host Disease (GVHD)
Verified date | May 2022 |
Source | University of Salamanca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Range of motion, antropometric measurements, quality of life questionnaire and 2 minutes walk test will be implemented as an initial assessment. Physical exercise program will take 2 sessions a week for six months, and several follow-ups: before, during and after treatment.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | July 30, 2023 |
Est. primary completion date | May 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Allogenic Transplantation patients with Graft versus host disease Exclusion Criteria: - Cognitive impairment - Physical limitation from other pathologies |
Country | Name | City | State |
---|---|---|---|
Spain | University of Salamanca | Salamanca |
Lead Sponsor | Collaborator |
---|---|
University of Salamanca |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SF36 Questionnaire | Quality of life | baseline and post-intervention (24 weeks) | |
Primary | 2 minutes walk test | walking for 2 minutes without rest | baseline and post-intervention (24 weeks) | |
Primary | Hands strength | Dynamometer | baseline and post-intervention (24 weeks) | |
Primary | Active range of motion | P-ROM. Active ROM will be compared with standard pictures (1-4 points for lower limb and 1-7 points for upper limb) | baseline and post-intervention (24 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
Active, not recruiting |
NCT04522843 -
Analysis of Intestinal Defensin Expression in Acute GVHD
|
||
Recruiting |
NCT05718791 -
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
|
||
Recruiting |
NCT05368181 -
MAP-guided Preemptive Therapy of aGvHD
|
Phase 2 | |
Withdrawn |
NCT05443464 -
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
|
Phase 1 | |
Not yet recruiting |
NCT06315309 -
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
|
Phase 2 | |
Terminated |
NCT04220632 -
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT04284904 -
Role of aGVHD Biomarkers on aGVHD Risks
|
||
Not yet recruiting |
NCT06164288 -
Safety and Efficacy Study of hAESCs Therapy for aGVHD
|
Phase 1 | |
Recruiting |
NCT06462365 -
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
|
Phase 1 |